{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:38:44Z","timestamp":1790069924259,"version":"4.0.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T00:00:00Z","timestamp":1554940800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["UMO-2014\/14\/M\/NZ5\/00441"],"award-info":[{"award-number":["UMO-2014\/14\/M\/NZ5\/00441"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s12185-019-02642-w","type":"journal-article","created":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T17:11:23Z","timestamp":1555002683000},"page":"102-106","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Germline missense NF1 mutation in an elderly patient with a blastic plasmacytoid dendritic cell neoplasm"],"prefix":"10.1007","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1732-8964","authenticated-orcid":false,"given":"Andrzej","family":"Szczepaniak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Machnicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Gniot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"P\u0119pek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Rydzanicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafa\u0142","family":"P\u0142oski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Ka\u017amierczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Stok\u0142osa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Lewandowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,11]]},"reference":[{"issue":"20","key":"2642_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood"},{"issue":"4","key":"2642_CR2","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/ajh.2830470406","volume":"47","author":"M Adachi","year":"1994","unstructured":"Adachi M, Maeda K, Takekawa M, Hinoda Y, Imai K, Sugiyama S, et al. High expression of CD56 (N-CAM) in a patient with cutaneous CD4-positive lymphoma. Am J Hematol. 1994;47(4):278\u201382.","journal-title":"Am J Hematol"},{"issue":"2","key":"2642_CR3","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/eji.200324531","volume":"34","author":"L Chaperot","year":"2004","unstructured":"Chaperot L, Perrot I, Jacob M-C, Blanchard D, Salaun V, Deneys V, et al. Leukemic plasmacytoid dendritic cells share phenotypic and functional features with their normal counterparts. Eur J Immunol. 2004;34(2):418\u201326.","journal-title":"Eur J Immunol"},{"issue":"2","key":"2642_CR4","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2013-05-500413","volume":"122","author":"L Boiocchi","year":"2013","unstructured":"Boiocchi L, Lonardi S, Vermi W, Fisogni S, Facchetti F. BDCA-2 (CD303): a highly specific marker for normal and neoplastic plasmacytoid dendritic cells. Blood. 2013;122(2):296\u20137.","journal-title":"Blood"},{"key":"2642_CR5","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"S Swerdlow","year":"2008","unstructured":"Swerdlow S. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008.","edition":"4"},{"issue":"4","key":"2642_CR6","doi-asserted-by":"publisher","first-page":"564","DOI":"10.5858\/arpa.2013-0101-RS","volume":"138","author":"Y Shi","year":"2014","unstructured":"Shi Y, Wang E. Blastic plasmacytoid dendritic cell neoplasm: a clinicopathologic review. Arch Pathol Lab Med. 2014;138(4):564\u20139.","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"2642_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/PAS.0b013e3181c5e26b","volume":"34","author":"C Cota","year":"2010","unstructured":"Cota C, Vale E, Viana I, Requena L, Ferrara G, Anemona L, et al. Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm\u2014morphologic and phenotypic variability in a series of 33 patients. Am J Surg Pathol. 2010;34(1):75\u2013877.","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"2642_CR8","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3324\/haematol.2012.072645","volume":"98","author":"L Pagano","year":"2013","unstructured":"Pagano L, Valentini CG, Pulsoni A, Fisogni S, Carluccio P, Mannelli F, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013;98(2):239\u201346.","journal-title":"Haematologica"},{"key":"2642_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.leukres.2018.01.013","volume":"66","author":"PC Boddu","year":"2018","unstructured":"Boddu PC, Wang SA, Pemmaraju N, Tang Z, Hu S, Li S, et al. 8q24\/MYC rearrangement is a recurrent cytogenetic abnormality in blastic plasmacytoid dendritic cell neoplasms. Leukemia Res. 2018;66:73\u20138.","journal-title":"Leukemia Res"},{"issue":"12","key":"2642_CR10","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1038\/s41375-018-0154-5","volume":"32","author":"K Sakamoto","year":"2018","unstructured":"Sakamoto K, Katayama R, Asaka R, Sakata S, Baba S, Nakasone H, et al. Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response. Leukemia. 2018;32(12):2590\u2013603.","journal-title":"Leukemia"},{"issue":"3","key":"2642_CR11","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/j.1365-2141.2010.08556.x","volume":"153","author":"F Jardin","year":"2011","unstructured":"Jardin F, Ruminy P, Parmentier F, Troussard X, Vaida I, Stamatoullas A, et al. TET2 and TP53 mutations are frequently observed in blastic plasmacytoid dendritic cell neoplasm. Br J Haematol. 2011;153(3):413\u20136.","journal-title":"Br J Haematol"},{"issue":"4","key":"2642_CR12","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/leu.2013.283","volume":"28","author":"J Menezes","year":"2014","unstructured":"Menezes J, Acquadro F, Wiseman M, Gomez-Lopez G, Salgado RN, Talavera-Casanas JG, et al. Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. Leukemia. 2014;28(4):823\u20139.","journal-title":"Leukemia"},{"issue":"6","key":"2642_CR13","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/leu.2010.69","volume":"24","author":"A Tefferi","year":"2010","unstructured":"Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010;24(6):1128\u201338.","journal-title":"Leukemia"},{"issue":"10","key":"2642_CR14","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1200\/JCO.2010.32.7742","volume":"29","author":"KH Metzeler","year":"2011","unstructured":"Metzeler KH, Maharry K, Radmacher MD, Mr\u00f3zek K, Margeson D, Becker H, et al. TET2 mutations improve the new european leukemianet risk classification of acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol. 2011;29(10):1373\u201381.","journal-title":"J Clin Oncol"},{"key":"2642_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40246-017-0109-3","volume":"11","author":"C Philpott","year":"2017","unstructured":"Philpott C, Tovell H, Frayling IM, Cooper DN, Upadhyaya M. The NF1 somatic mutational landscape in sporadic human cancers. Hum Genom. 2017;11:13.","journal-title":"Hum Genom"},{"key":"2642_CR16","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1182\/asheducation-2015.1.571","volume":"1","author":"J Haroche","year":"2015","unstructured":"Haroche J, Abla O. Uncommon histiocytic disorders: Rosai-Dorfman, juvenile xanthogranuloma, and Erdheim-Chester disease. Hematol Am Soc Hematol Edu Program. 2015;1:571\u20138.","journal-title":"Hematol Am Soc Hematol Edu Program"},{"issue":"4","key":"2642_CR17","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ajh.23403","volume":"88","author":"E Boudry-Labis","year":"2013","unstructured":"Boudry-Labis E, Roche-Lestienne C, Nibourel O, Boissel N, Terre C, Perot C, et al. Neurofibromatosis-1 gene deletions and mutations in de novo adult acute myeloid leukemia. Am J Hematol. 2013;88(4):306\u201311.","journal-title":"Am J Hematol"},{"key":"2642_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13000-018-0692-1","volume":"13","author":"JH Gralewski","year":"2018","unstructured":"Gralewski JH, Post GR, van Rhee F, Yuan Y. Myeloid transformation of plasma cell myeloma: molecular evidence of clonal evolution revealed by next generation sequencing. Diagn Pathol. 2018;13:15.","journal-title":"Diagn Pathol"},{"key":"2642_CR19","doi-asserted-by":"crossref","unstructured":"Kiuru M, Busam KJ. The NF1 gene in tumor syndromes and melanoma. Lab Investig J Tech Methods Pathol. 2017;97(2):146\u201357.","DOI":"10.1038\/labinvest.2016.142"},{"issue":"1","key":"2642_CR20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1634\/theoncologist.2010-0181","volume":"17","author":"S Patil","year":"2012","unstructured":"Patil S, Chamberlain RS. Neoplasms associated with germline and somatic NF1 gene mutations. Oncologist. 2012;17(1):101\u201316.","journal-title":"Oncologist"},{"issue":"16","key":"2642_CR21","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1158\/1078-0432.CCR-09-2639","volume":"16","author":"B Parkin","year":"2010","unstructured":"Parkin B, Ouillette P, Wang Y, Liu Y, Wright W, Roulston D, et al. NF1 inactivation in adult acute myelogenous leukemia. Clin Cancer Res. 2010;16(16):4135\u201347.","journal-title":"Clin Cancer Res"},{"key":"2642_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bty897","author":"C Kopanos","year":"2018","unstructured":"Kopanos C, Tsiolkas V, Kouris A, Chapple CE, Albarca Aguilera M, Meyer R, et al. VarSome: the human genomic variant search engine. Bioinformatics. 2018. \n                    https:\/\/doi.org\/10.1093\/bioinformatics\/bty897","journal-title":"Bioinformatics."},{"issue":"D1","key":"2642_CR23","doi-asserted-by":"publisher","first-page":"D941","DOI":"10.1093\/nar\/gky1015","volume":"47","author":"JG Tate","year":"2019","unstructured":"Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2019;47(D1):D941\u2013D947947.","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"2642_CR24","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1002\/humu.22162","volume":"33","author":"L Thomas","year":"2012","unstructured":"Thomas L, Richards M, Mort M, Dunlop E, Cooper DN, Upadhyaya M. Assessment of the potential pathogenicity of missense mutations identified in the GTPase-activating protein (GAP)-related domain of the neurofibromatosis type-1 (NF1) gene. Hum Mutation. 2012;33(12):1687\u201396.","journal-title":"Hum Mutation"},{"issue":"2","key":"2642_CR25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jmoldx.2010.09.002","volume":"13","author":"MC Valero","year":"2011","unstructured":"Valero MC, Martin Y, Hernandez-Imaz E, Marina Hernandez A, Melean G, Valero AM, et al. A highly sensitive genetic protocol to detect NF1 mutations. J Mol Diagn. 2011;13(2):113\u201322.","journal-title":"J Mol Diagn"},{"key":"2642_CR26","doi-asserted-by":"crossref","unstructured":"Gottfried ON, Viskochil DH, Couldwell WT. Neurofibromatosis type 1 and tumorigenesis: molecular mechanisms and therapeutic implications. Neurosug Focus. 2010;28(1):E8.","DOI":"10.3171\/2009.11.FOCUS09221"},{"key":"2642_CR27","doi-asserted-by":"publisher","first-page":"15102","DOI":"10.1038\/ncomms15102","volume":"8","author":"F Pan","year":"2017","unstructured":"Pan F, Wingo TS, Zhao Z, Gao R, Makishima H, Qu G, et al. Tet2 loss leads to hypermutagenicity in haematopoietic stem\/progenitor cells. Nat Commun. 2017;8:15102.","journal-title":"Nat Commun"},{"issue":"1","key":"2642_CR28","doi-asserted-by":"publisher","first-page":"5014","DOI":"10.1038\/s41467-018-07452-y","volume":"9","author":"J-P Brosseau","year":"2018","unstructured":"Brosseau J-P, Liao C-P, Wang Y, Ramani V, Vandergriff T, Lee M, et al. NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. Nat Commun. 2018;9(1):5014.","journal-title":"Nat Commun"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-019-02642-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-019-02642-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-019-02642-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T23:37:48Z","timestamp":1586475468000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-019-02642-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,11]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["2642"],"URL":"https:\/\/doi.org\/10.1007\/s12185-019-02642-w","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,11]]},"assertion":[{"value":"1 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}